Cesar L A, Amato R, Pfeferman E, Serrano C V, Ramires J A, Bellotti G, Pileggi F
Instituto do Coração do Hospital das Clínicas, FMUSP.
Arq Bras Cardiol. 1991 May;56(5):381-3.
To evaluate the efficacy and safety of intravenous hydralazine in arterial hypertension.
12 patients, mean age 45.33 +/- 15.82.8 men and 4 women all of them with systolic (S) arterial pressure (AP) greater than or equal to 180 and or diastolic (D) greater than or equal to 126 mmHg with symptoms like headache, in characteristic thoracic pain and others but without an hypertensive emergency neither acute manifestation of hypertensive encephalopathy through fundi examination were studied. The AP was taken 10 minutes after rest (initial) and 5, 15, 30 and 60 min (final) after intravenous administration of hydralazine-HCL (5 mg) which was repeated when at least 20% AP reduction was not achieved.
The initial and final SAP, DAP and heart rate (HR) were 208 +/- 19.4 and 176 +/- 17.2 (p less than 0.0001), 133 +/- 11.3 and 112 +/- 11.5 (p less than 0.001) and 72 +/- 12.9 and 80 +/- 15.5 (NS), respectively. Side effects related to the drug were observed in 3 (25%) patients. One had symptomatic orthostatic hypotension, the second had precordial pain with ST-T changes compatible with myocardial ischemia and the third presented a thorax and abdominal cutaneous erythema, but all of them reversible.
Intravenous hydralazine-HC1 is an alternative when rapid arterial pressure reduction is needed.
评估静脉注射肼屈嗪治疗动脉高血压的疗效和安全性。
12例患者，平均年龄45.33±15.82岁，男性8例，女性4例，均有收缩压（S）大于或等于180mmHg和/或舒张压（D）大于或等于126mmHg，伴有头痛、典型胸痛等症状，但无高血压急症，通过眼底检查也无高血压脑病的急性表现。在休息10分钟后（初始值）以及静脉注射盐酸肼屈嗪（5mg）后5、15、30和60分钟（终末值）测量血压。若血压降低未达到至少20%，则重复给药。
初始和终末收缩压、舒张压及心率（HR）分别为208±19.4和176±17.2（p<0.0001）、133±11.3和112±11.5（p<0.001）以及72±12.9和80±15.5（无显著性差异）。3例（25%）患者出现与药物相关的副作用。1例出现症状性体位性低血压，第2例出现与心肌缺血相符的ST-T改变的心前区疼痛，第3例出现胸部和腹部皮肤红斑，但所有副作用均可逆。
当需要快速降低动脉血压时，静脉注射盐酸肼屈嗪是一种选择。
